动脉粥样硬化 - 1.pptVIP

其它： 胆固醇吸收抑制剂 依折麦布ezetimibe 烟酸类 Nicotinic acid Decreasing LDL-C Increasing HDL-C Niacin(烟酸) 不饱和脂酸类 目标水平（mmol/L） AS 危险因素 TC LDL-C TG — － 5.72 3.64 1.69 + + 4.68 2.60 1.69 动脉粥样硬化的防治 3. 抗血小板药 Antiplatelet agents ①TXA2 inhibitors： Aspirin (阿司匹林) ②ADP depending： clopidogrel (氯吡格雷) ③血小板糖蛋白Ⅱb/Ⅲa受体阻滞剂 Platelet AP BⅡ/AⅢ blocker： Tirofiban(替罗非班) abciximab(阿昔单抗) 动脉粥样硬化的防治 4. Anticougulant and Thrombolysis agents (抗凝药和溶血栓药) Haperin LMWH UK SK tPA 5. others for HP DM and so on 三 Inteventional and surgery angioplasty, stentng, Bypass * * Atherosclerosis is a complex disease. Atherosclerotic plaques can be subdivided in accordance with their age and state of development. It is the newly formed lesions with a large lipid core, thin capped, which are fragile and therefore likely to rupture and lead to an acute ischemic event. * * * * * * Slide 3 Atherothrombosis: a Generalized and Progressive Process Atherothrombosis is the common underlying disease process for MI, ischemia and vascular death. ACS are classic examples of atherothrombosis (plaque rupture and thrombus formation). ACS (in common with ischemic stroke and critical leg ischemia) are typically caused by rupture or erosion of an atherosclerotic plaque followed by formation of a platelet-rich thrombus. Atherosclerosis is an ongoing process affecting mainly large and medium-sized arteries, which can begin in childhood and progress throughout a person’s lifetime. Stable atherosclerotic plaques may encroach on the lumen of the artery and cause chronic ischemia, resulting in (stable) angina pectoris or intermittent claudication, depending on the vascular bed affected. Unstable atherosclerotic plaques may rupture, leading to the formation of